Nuvisan Icb GmbH
Records under this name other than patents Nuvisan Icb GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 4 of 4 · Back to Nuvisan Icb GmbH
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,964,953 | Substituted Aminothiazoles as Dgkzeta Inhibitors for Immune Activation now held by Bayer Aktiengesellschaft In force · High confidence | In force | High confidence | |
| US 12,760,047 | Phosphorus Derivatives as SOS1 Inhibitors now held by Bayer Aktiengesellschaft In force · High confidence | In force | High confidence | |
| 18/275,978 | MAP4K1 Inhibitors now held by Deutsches Krebsforschungszentrum Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/871,455 | IMIDAZO(1,2-1)PYRIDINE Derivatives as RIPK2 Inhibitors now held by Mirador Therapeutics, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |